pharma
Novartis
Novartis is a pharma organization headquartered in Basel, CH. NovaPharmaNews links 0 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sourc
Company details
- Status
- Public
- HQ
- Basel, CH
- Programs
- 0
- Drugs
- 0
- Patents
- 0
Quick answer
Novartis is a pharma organization headquartered in Basel, CH. NovaPharmaNews links 0 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources.
Company snapshot
Novartis is a pharma organization headquartered in Basel, CH. NovaPharmaNews links 0 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources.
- Profile assembled from SEC, FDA, ClinicalTrials.gov, and USPTO public sources.
Public regulatory, clinical, patent, and corporate records for Novartis. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- approval
Layoff Tracker: Takeda and Novartis Restructure Amid Industry Changes
- approval
Layoff Tracker: Takeda and Novartis Restructuring Impact
- approval
Takeda and Novartis Layoffs: Implications for Pharma Industry
- approval
Novartis Strengthens Prostate Cancer Treatment with Pluvicto
- approval
Novartis remibrutinib wins Phase 3 in CSU: what it means
- approval
Novartis remibrutinib wins Phase 3 in chronic spontaneous urticaria
Recent coverage
Novartis remibrutinib wins Phase 3 in CSU: what it means
Novartis remibrutinib is an oral, highly selective BTK inhibitor with Phase 3 success in chronic spontaneous urticaria. This plan frames the catalyst for BD teams, investors, and analysts, including efficacy, safety, and next milestones.
Novartis remibrutinib wins Phase 3 in chronic spontaneous urticaria
Novartis remibrutinib has Phase 3 support in chronic spontaneous urticaria, with evidence of early symptom improvement and sustained efficacy through 52 weeks. This plan frames the result for BD teams, investors, and analysts, including regulatory context and what to watch next.
Legend Biotech surges on early in vivo CAR-T data for lymphoma
Legend Biotech's experimental in vivo CAR-T therapy, LB2501, reduced or eliminated disease signs in all treated lymphoma patients in a first-in-human trial. The data fuel hopes that the approach could compete with ex vivo therapies like Novartis' Kymriah.
BMS Expands in Texas While Novartis Faces Tenant Challenges
Bristol Myers Squibb is planning a new campus in Texas, while Novartis is facing eviction issues with a tenant in Slovenia. These developments could reshape the competitive landscape.
Congress & presentations
- CongressPharma Manufacturing World
- Presentationabelacimab (SPAF) phase 3 readout
Momentum signals
Momentum
Proprietary activity score for Novartis.
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitive landscape
Recent activity
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Novartis?
-
Is Novartis publicly traded?
-
What drugs does Novartis develop or market?
-
What are the latest developments for Novartis?
-
What therapeutic areas does Novartis focus on?